Better Therapeutics- Tradeable Rights - March 2021 Operating Income

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) currently reports a operating income of $-30M as of September 2023. That compares with $-42M in the prior-year period — up 29.6% year over year. Use the charts on this page to explore Better Therapeutics- Tradeable Rights - March 2021's operating income history and peer comparisons.

Better Therapeutics- Tradeable Rights - March 2021's operating income increased from $-42M to $-30M — a 29.6% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Better Therapeutics- Tradeable Rights - March 2021 reported $-30M in operating income as of September 2023. That compares with $-42M in the prior-year period — up 29.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Better Therapeutics- Tradeable Rights - March 2021, and consider following MCADR for alerts when major investors trade the stock.